Center of Excellence: Migraine: News & Perspective

• FDA Approves Intranasal DHE (Trudhesa) for Acute Migraine Trudhesa uses a proprietary technology to deliver DHE to the upper nasal space, bypassing the gut and potential absorption problems, and can be taken anytime during an acute migraine attack.
  FDA Approvals, September 03, 2021
• Behavioral Therapy for Migraine Prevention Our experts shed light on behavioral strategies that have proven effective for adults, as well as children and adolescents, with migraine.
  American Headache Society and Medscape, August 31, 2021
• Atogepant Reduces Migraine Days: ADVANCE Trial Published Results from the phase 3 trial indicate that atogepant reduces migraine and headache days compared with placebo; and it had a favorable safety profile at all doses studied.
  Medscape Medical News, August 25, 2021
• Intranasal DHE Safe for Acute Migraine: STOP 301 Published An intranasal formulation of dihydroergotamine is safe and well-tolerated for the treatment of acute migraine, according to newly published findings from the open-label phase 3 STOP-301 trial.
  Medscape Medical News, August 18, 2021
• Virtual Roller-coaster May Explain the Ups and Downs of Migraine A virtual roller-coaster ride is shedding new light on the migraine brain and explains the mechanisms underlying common symptoms, including nausea, dizziness, and increased activity in certain brain regions.
  Medscape Medical News, July 28, 2021
• AHS Releases Updated Guidance on New Migraine Treatments An updated consensus statement from the American Headache Society offers detailed recommendations on the use of novel acute and preventive treatments in adults with migraine.
  Medscape Medical News, July 16, 2021
• Diet Rich in Omega-3s Linked to Fewer Migraines, Less Pain A diet rich in omega-3 was associated with two fewer headache days per month, and a diet high in omega-3 and low in omega-6 resulted in four fewer monthly migraine days.
  Medscape Medical News, July 06, 2021
• New Migraine Treatments: Which Is Right for Your Patients? Dr Burch discusses the array of therapeutic options and what to consider when prescribing them.
  American Headache Society and Medscape, July 02, 2021
• Impact of COVID-19 on Acute Migraine Patients   What is causing this headache? Acute migraine, COVID-19, my mask, or just the stress of the pandemic? Dr. Randolph Evans helps us to answer these questions.
  Medscape, June 30, 2021
• What Practice Challenges Do You Face in the Treatment of Acute Migraine?   What's standing in our way? Dr. Randolph Evans takes on the many challenges of both diagnosing and taking on the obstacles to treating migraine.
  Medscape, June 28, 2021
• Acute Migraine Among Headache Specialists   Headache specialist and migraine sufferer Dr Randolph Evans tells his acute migraine patients that he "feels their pain."
  Medscape, June 28, 2021
• Migraine Highlights From 2021 AHS Meeting   Dr Brian Grosberg reviews key abstracts on migraine care presented at the 2021 American Headache Society virtual meeting, including the phase 3 ADVANCE trial and insights from CaMEO.
  Medscape, June 25, 2021
• Two Mentors Who Shaped a Headache Specialist's Philosophy and Approach   Headache specialist Dr Stephanie Nahas discusses the "one-two-three punch" philosophy of managing acute migraine, and other lessons that she learned from her mentors.
  Medscape, June 23, 2021
• Evolution of Acute Migraine Treatment Guidelines   Dr. Randolph Evans reflects on the advances in acute treatment of migraine and the guidelines that support them.
  Medscape, June 22, 2021
• AHS 2021 Novel NSAID–Triptan Drug Effectively Relieves Migraine Pain An investigational oral treatment is more effective than placebo in providing pain freedom and freedom from the most bothersome symptom at 2 hours, new phase 3 results suggest.
  Medscape Medical News, June 22, 2021
• EAN 2021 Women With Migraine 'High-Risk' Patients During Pregnancy Pregnant women with migraine should be considered high-risk patients and be managed with specialized neurologic services, new research suggests.
  Medscape Medical News, June 22, 2021
• AHS 2021 Rapid Pain Relief With Eptinezumab for Episodic Migraine During a migraine attack, the IV monoclonal antibody eptinezumab provides freedom from pain in as little as 1 hour after administration, new research suggests.
  Medscape Medical News, June 16, 2021
• AHS 2021 No Increased Risk of Hypertension With Erenumab? The migraine medication erenumab appeared to pose no increased risk of hypertension, easing earlier concerns. Nevertheless, investigators noted that more research is needed to confirm the findings.
  Medscape Medical News, June 15, 2021
• AHS 2021 Migraine Linked to More COVID-19 Infections, Symptoms Patients with migraine are more susceptible to contracting COVID-19, more sensitive to the development of COVID-related symptoms, or both, new research suggests.
  Medscape Medical News, June 15, 2021
• AHS 2021 Moving More, Sitting Less Is Vital During Migraine Encouraging patients with migraine to participate in physical exercise is important for managing symptoms and overall health ― as is cutting down excessive periods of uninterrupted sitting, experts say.
  Medscape Medical News, June 15, 2021